Recent reports of Nipah virus (NiV) infections in West Bengal, India, have renewed global public health concerns, driving increased focus on research into this highly lethal pathogen. In response, Sino Biological, Inc., a recognized leader in recombinant protein technologies, has accelerated the development and availability of essential research reagents to support worldwide efforts against NiV.
Nipah virus: A critical emerging threat
Nipah virus belongs to the Paramyxoviridae family and is designated by the World Health Organization (WHO) as a priority pathogen due to its high epidemic potential and fatality rate, estimated at 40–75%. With no licensed vaccines or targeted antiviral therapies currently available, access to high-quality, biologically active research reagents remains vital for advancing preventive and therapeutic solutions.
Advanced reagent solutions for NiV research
To address urgent research needs, Sino Biological has introduced a portfolio of high-purity NiV G and F proteins, which play a key role in viral entry studies and antibody screening. The company is also accelerating the development of NiV N proteins, along with pre-fusion and post-fusion F trimer proteins. These N proteins are derived from the latest reported viral strains, providing improved sequence accuracy compared with older variants containing multiple mutations. Additionally, Sino Biological offers ProPure™ endotoxin-free (ET-free) versions of NiV G and F proteins, specifically optimized for vaccine research requiring stringent endotoxin control and high immunogen purity.
